<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341951</url>
  </required_header>
  <id_info>
    <org_study_id>PIMERIndia</org_study_id>
    <nct_id>NCT01341951</nct_id>
  </id_info>
  <brief_title>Granulocyte Colony Stimulating Factor (G-CSF) in Acute Liver Failure and Alcoholic Hepatitis</brief_title>
  <acronym>G-CSF</acronym>
  <official_title>G-CSF in Acute Liver Failure and Alcoholic Hepatitis - A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Postgraduate Institute of Medical Education and Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Postgraduate Institute of Medical Education and Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Granulocyte colony stimulating factor in acute liver failure and alcoholic hepatitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study 4 groups have been taken. Two groups of cases including Alcoholic patients and
      acute liver failure which are given G-CSF therapy and two groups of controls given standard
      therapy. Primary end point is to see the mobilization of CD-34 hematopoietic cells and
      survival. Secondary end point is to see the clinical and biochemical improvement in liver
      functions.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Mobilization of CD34 cells in the peripheral blood, a surrogate marker for hematopoietic stem cell mobilization</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical and biochemical improvement in liver functions</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Liver Failure, Acute</condition>
  <arm_group>
    <arm_group_label>G-CSF therapy in acute liver failure and alcoholic hepatitis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G-CSF therapy given in cases with acute liver failure and alcoholic hepatitis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Granulocyte colony stimulating factor</intervention_name>
    <description>300 I.U twice daily for 5 days</description>
    <arm_group_label>G-CSF therapy in acute liver failure and alcoholic hepatitis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Acute Liver failure as defined by AASLD.65

          -  Patients with Alcoholic hepatitis defined as follows: decades of heavy alcohol use
             (mean intake, approximately 100 g per day).The combination of an aspartate
             aminotransferase level that is elevated (but &lt;300 IU per milliliter) and a ratio of
             the aspartate aminotransferase level to the alanine aminotransferase level that is
             more than 2, a total serum bilirubin level of more than 5 mg per deciliter (86 μmol
             per liter), an elevated INR, and neutrophilia.

        Exclusion Criteria:

        • Known hypersensitivity to filgrastim

          -  creatinine &gt; 150 µmol/L

          -  infection or hemorrhage within the last 10 days

          -  documented hepatocellular carcinoma

          -  hepatitis B,C or human immunodeficiency virus seropositivity and pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>virendra singh</last_name>
    <role>Principal Investigator</role>
    <affiliation>Postgraduate Institute of Medical Education and Research Chandigarh India</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Arun Sharma, DM</last_name>
    <phone>08872721666</phone>
    <email>drarunvashisht@yahoo.co.in</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Virendra Singh</last_name>
    <phone>09914209338</phone>
    <email>virendrasingh100@hotmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Postgraduate Institute of Medical Education &amp; Research Chandigarh India</name>
      <address>
        <city>Chandigarh</city>
        <zip>1600012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arun Sharma, DM</last_name>
      <phone>08872721666</phone>
      <email>drarunvashisht@yahoo.co.in</email>
    </contact>
    <investigator>
      <last_name>Arun Sharma, DM Hepatology</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <reference>
    <citation>Spahr L, Lambert JF, Rubbia-Brandt L, Chalandon Y, Frossard JL, Giostra E, Hadengue A. Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial. Hepatology. 2008 Jul;48(1):221-9. doi: 10.1002/hep.22317.</citation>
    <PMID>18537187</PMID>
  </reference>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 15, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <last_update_submitted>April 25, 2011</last_update_submitted>
  <last_update_submitted_qc>April 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Virendra Singh</name_title>
    <organization>Postgraduate Institute of Medical Education and Research, Chandigarh, India</organization>
  </responsible_party>
  <keyword>liver failure, Acute</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Hepatitis, Alcoholic</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

